|Day Low/High||149.33 / 152.53|
|52 Wk Low/High||106.11 / 151.06|
Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.
I continue to believe downside risks far outweigh the risks of a near-term rally.
In a "take no pain, take no prisoners" market, health care stocks languish.
We used this week's declines to add to our positions in Teligent, Builders FirstSource and Sonus Networks.
Shares of the drug distributor were falling sharply Friday.
The drugmaker's shares were hammered Friday on news that the industry is slashing prices.
Hershey shares got an early Halloween treat Friday after earnings topped analyst forecasts.
McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.
The pricing structure of the healthcare and drug distribution industry has been wrecked and Wall Street is taking down those stocks as a result, says Jim Cramer.
Energy and consumer defensive names dominate on the bearish side.
Keep your powder dry and see if MCK tries to makes a double bottom.
McKesson is down 10 percent year-to-date due to the heated political debate over drug pricing but the stock is too cheap to ignore.
In the case of McKesson, Value Line system doesn't do investors any favors.
There are issues everywhere, in almost every group.
But try to have your buy orders below the market, in the $165 area.
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
Undeterred by previous snubs, spicemaker McCormick makes a revised approach to Britain's Premier Foods, raising the proposed enterprise value to $2.16 billion.
TheStreet’s Jim Cramer says he thinks Visa will go up substantially, and that consumer products companies Kimberly Clark and Procter & Gamble are ‘screaming buys.'
U.S. futures are falling premarket.
McKesson revealed Thursday a pair of acquisitions that will grow its oncology business.
Why be afraid to own a world leader in health care at a multiyear best valuation?
After reading the chart action, we see $120 as the next stopping point.